NiWO4 catalyzed expeditious synthesis of pyranopyrazoles

In this paper, a multicomponent green rapid method for synthesis of pyranopyrazoles is reported using NiWO4 in water in 15 min. Environment friendly features such as energy efficiency, aqueous medium, no hazardous solvent, no chromatography, in addition to the short reaction time, catalyst reusability and substrate tolerance without affecting yield proves the near perfectness of this method for synthesis of medicinally important pyranopyrazoles. NiWO4, ZnWO4 and CuWO4 have been synthesized using extract of plant Phyllantus amarus. The prepared catalysts have been characterized by XRD, EDX and SEM

Pivalic acid assisted Biginelli reaction for synthesis of dihydropyrimidinones and dihydrothiopyrimidinones

Herein is provided an alternate, simple, multigram scale, efficient route for Biginelli reaction for synthesis of dihydropyrimidinones using urea, ethylacetatoacetate, and benzaldehyde with pivalic acid

Pivalic acid assisted Biginelli reaction for synthesis of dihydropyrimidinones and dihydrothiopyrimidinones

677-681Herein is provided an alternate, simple, multigram scale, efficient route for Biginelli reaction for synthesis of dihydropyrimidinones using urea, ethylacetatoacetate, and benzaldehyde with pivalic acid

Unique synthesis of isochromenoindolone <em>via</em> reductive-oxidative cyclisation approach</span>

104-108A unique reductive-oxidative cyclisation approach for synthesis of isochromeno[4,3-b]indol-5(11H)-one from nitrostrylbenzoate is described

NiWO4 catalyzed expeditious synthesis of pyranopyrazoles

196-201In this paper, a multicomponent green rapid method for synthesis of pyranopyrazoles is reported using NiWO4 in water in 15 min. Environment friendly features such as energy efficiency, aqueous medium, no hazardous solvent, no chromatography, in addition to the short reaction time, catalyst reusability and substrate tolerance without affecting yield proves the near perfectness of this method for synthesis of medicinally important pyranopyrazoles. NiWO4, ZnWO4 and CuWO4 have been synthesized using extract of plant Phyllantus amarus. The prepared catalysts have been characterized by XRD, EDX and SEM

Long-term (180-Day) outcomes in critically Ill patients with COVID-19 in the REMAP-CAP randomized clinical trial

Importance The longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown. Objective To determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes. Design, Setting, and Participants Prespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022. Interventions Patients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401). Main Outcomes and Measures The main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83. Results Among 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies. Conclusions and Relevance Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months